AdvanDx adds $8m to series C
This article was originally published in Clinica
AdvanDx, developer of molecular diagnostic tests for bacterial infections, has raised $8m in the second tranche of its series C financing round. The funds, which were provided by existing shareholders SLS Venture and LD Pensions, will be used to expand AdvanDx’s international sales and marketing activities and grow its product portfolio. In conjunction with the financing, the Woburn, Massachusetts firm also elected Tina Christensen to its board of directors. Ms Christensen is the vice-president and CFO of International Health Insurance danmark, a Danish health and medical travel insurance provider.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.